ACTRN12624000824561
Not yet recruiting
Phase 1
Clearview-BC: A phase 1 PET-CT study to evaluate the safety, biodistribution and pharmacokinetics of 89Zr-hu/mo-10D7 in patients with Bladder Cancer
niversity of Queensland0 sites20 target enrollmentJuly 4, 2024
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Metastatic Bladder Cancer
- Sponsor
- niversity of Queensland
- Enrollment
- 20
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Provide a signed and dated informed consent form
- •Be willing to comply with all study procedures and be available for the duration of the study
- •Adults greater than or equal to 18 years
- •Have histologically proven invasive bladder cancer
- •Visible metastatic disease on diagnostic CT and/or FDG\-PET imaging
- •CDCP1 expression proven on tumour sample
- •Expected survival more than 3 months
- •Women of reproductive potential must use highly effective contraception and abstain from getting period during the trial period
- •Adequate organ function. Out of range values that are not clinically significant will be permitted, except for the following laboratory parameters, which must be within the ranges specified:
- •Serum AST and ALTless than or equal to 2\.5 x ULN
Exclusion Criteria
- •History of major immunologic reaction to any IgG containing agent
- •Prior or ongoing clinically significant illness, medical condition(s), surgical history, physical finding, electrocardiogram (ECG) finding, or laboratory abnormality that, in the investigator’s opinion, could places the subject at an unacceptably high risk, adversely affect the safety of the subject or impair the assessment of study results
- •Subject is pregnant, lactating, or and/or plans to become pregnant within the trial period
- •Exposure within the past 5 years to chimeric or murine antibodies
- •Exposure to a radiopharmaceuticals within the washout period (washout 10 half\-lives of the radionuclide)
- •Concurrent participation in another clinical trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A clinical trial to see whether outcomes in Hodgkins Lymphoma can be improved by using increased intensity therapy in interim PET scan positive patientsHealth Condition 1: null- Advanced Hodgkins Lymphoma (Stage IIb, III, IV)Health Condition 2: C819- Hodgkin lymphoma, unspecifiedHealth Condition 3: C819- Hodgkin lymphoma, unspecifiedCTRI/2012/06/002741Cancer Institute50
Recruiting
Not Applicable
Diagnostic exam for renal cancerRBR-6p8pkvqFundação Antônio Prudente - AC Camargo Cancer Center
Recruiting
Not Applicable
Prospective Evaluation of the Use of PET-CT in HepatocarcinomaHepatocellular carcinomaC04.588.274.623RBR-3vxgjsjFundação Antônio Prudente - AC Camargo Cancer Center
Completed
Not Applicable
A study of changing the order of scans in making a diagnosis of lung cancer.ung cancerLung cancerCancer - Lung - Non small cellCancer - Lung - Small cellACTRN12618001789257Royal Brisbane and Womens Hospital168
Completed
Not Applicable
A pilot study of clinical usefulness of PET-CT and PET-MRI in cancer patients treated with medical tharapyCancerJPRN-UMIN000017136Department of Surgery, Fukushima Medical University100